Advertisement

Topics

Cancer Research UK partners with Biotecnol to deliver experimental solid tumour drug

05:39 EDT 10 Aug 2017 | Pharmafile

Cancer Research UK (CRUK) has announced a collaboration with Biotecnol, an immuno-oncology firm focused on the development of multifunctional antibodies in areas of unmet need, to develop an experimental treatment for advanced solid tumours

The agreement between the two organisations means that Biotecnol will leverage CRUK’s expertise in drug development to push its therapy, known only as Tb535H, through its first in-man Phase 1 clinical trial, while CRUK will benefit from shareholdings in its partner.

read more

Original Article: Cancer Research UK partners with Biotecnol to deliver experimental solid tumour drug

NEXT ARTICLE

More From BioPortfolio on "Cancer Research UK partners with Biotecnol to deliver experimental solid tumour drug"

Quick Search
Advertisement
 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...